The epidermal growth factor receptor (EGFR) is part of a family of plasma membrane
receptor tyrosine kinases that control many important cellular functions, from growth and …

Both cyclooxygenase (COX)-2 and epidermal growth factor receptor (EGFR) are thought to
play important roles in the pathogenesis of non-small cell lung cancer (NSCLC). A number …

Lung cancer is the leading cause of cancer death all over the world. The low 5-year survival
rate (under 15%) has changed minimally in the last 25 years. Amongst different types of lung …

Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung
cancer. Elevated tumor prostaglandin E2 (PGE2), a major COX-2 metabolite, levels have …

Abstract Cyclooxygenase 2 (COX-2) overexpression is found in a wide variety of human
cancers and is linked to all stages of tumorigenesis. Elevated tumor COX-2 expression is …

Cyclooxygenase-2 (COX-2) is a key enzyme in the production of prostaglandins and
thromboxanes from free arachidonic acid. Increasing evidence suggests that COX-2 plays a …

BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs)
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …

Preclinical studies suggest that cyclooxygenase (COX)-2 may be involved in the molecular
pathogenesis of some types of lung cancer. Most of the available studies point to its …

Lung cancer is the leading cause of cancer death in the United States. Although the low 5-
year survival rate (under 15%) has changed minimally in the last 25 years, new agents and …

Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early
event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with …